-- FactSetが調査したアナリストによると、クライム・バイオ（CLYM）の平均投資判断は「買い」、平均目標株価は18.69ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Price: $11.98, Change: $+0.53, Percent Change: +4.63%
Related Articles
Australia
RBC Capital Lifts Advanced Micro Devices Price Target to $400 From $325, Maintains Sector Perform Rating
Advanced Micro Devices (AMD) has an average rating of Buy and mean price target of $410.23, according to analysts polled by FactSet.Price: $411.71, Change: $+56.45, Percent Change: +15.89%
$AMD
Australia
RBC Capital Adjusts Astera Labs Price Target to $270 From $250, Maintains Outperform Rating
Astera Labs (ALAB) has an average rating of overweight and mean price target of $243.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $204.83, Change: $-10.86, Percent Change: -5.04%
$ALAB
Australia
RBC Lowers Price Target on Cogent Communications to $18 From $22, Keeps Sector Perform Rating
Cogent Communications (CCOI) has an average rating of overweight and mean price target of $23.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $17.45, Change: $-0.61, Percent Change: -3.41%
$CCOI